NASDAQ: ESTAEstablishment Labs Holdings Inc Stock
$72.45+0.30 (+0.42%)
Updated Aug 26, 2026
ESTA Price
$72.45
Fair Value Price
N/A
Market Cap
$2.16B
52 Week Low
$36.53
52 Week High
$97.40
P/E
-55.73x
P/B
99.93x
P/S
10.52x
PEG
N/A
Dividend Yield
N/A
Revenue
$245.82M
Earnings
-$38.89M
Gross Margin
70.5%
Operating Margin
-8.1%
Profit Margin
-15.8%
Debt to Equity
15.29
Operating Cash Flow
-$32M
Beta
1.67
Next Earnings
N/A
Ex-Dividend
N/A
Next Dividend
N/A
ESTA Overview
Establishment Labs Holdings Inc. operates as a medical technology enterprise specializing in the creation and commercialization of devices for aesthetic and reconstructive plastic surgery. The company is primarily recognized for its silicone gel-filled breast implants, sold under the Motiva Implants brand. Among these are the Motiva Ergonomix and Motiva Ergonomix2, which are distinctive, gravity-sensitive, round, soft silicone-gel-filled implants. Furthermore, Establishment Labs provides the Motiva Flora Tissue Expander for breast tissue and distributes the Puregraft range of products, utilized for the harvesting and redistribution of autologous adipose tissue. The firm markets its offerings across Europe, Latin America, the Asia-Pacific region, and other global markets, leveraging both a direct sales force and exclusive distributors. Founded in 2004, Establishment Labs has its main office situated in Alajuela, Costa Rica.
Zen Rating
Our proven quant model uses 115 proprietary factors, including AI, to determine ESTA's potential to beat the market
CHold
- Stocks with a Zen Rating of Hold (C) had an average return of +5.11% per year. Learn More
Zen Rating Component Grades
C
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.
Be the first to know about important ESTA news, forecast changes, insider trades & much more!
ESTA News
Overview
Due Diligence Score
–
Industry Average (29)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how ESTA scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
ESTA is unprofitable, so we are unable to calculate its intrinsic value according to an updated version of Benjamin Graham's Formula from "The Intelligent Investor"
Below Benjamin Graham Formula Value Valuation
ESTA is poor value based on its book value relative to its share price (99.93x), compared to the US Medical Devices industry average (3.34x)
P/B vs Industry Valuation
ESTA is unprofitable, so we... subscribe to Premium to read more.
PEG Value Valuation
There are 30 more ESTA due diligence checks available for Premium users.
Valuation
ESTA fair value
Fair Value of ESTA stock based on Discounted Cash Flow (DCF)
Price
$72.45
Fair Value
-$78.16
Undervalued by
192.69%
ESTA is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
ESTA price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-55.73x
Industry
24.46x
Market
18.15x
ESTA price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
99.93x
Industry
3.34x
ESTA is poor value based... subscribe to Premium to read more.
P/B vs Industry Valuation
ESTA's financial health
Profit margin
Revenue
$67.5M
Net Income
-$11.7M
Profit Margin
-17.4%
ESTA's cash burn is expected... subscribe to Premium to read more.
Interest Coverage Financials
ESTA's profit margin has increased... subscribe to Premium to read more.
Profit Margin Growth Financials
Assets to liabilities
Assets
$351.9M
Liabilities
$330.3M
Debt to equity
15.29
ESTA's short-term assets ($247.73M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
ESTA's long-term liabilities ($265.76M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
ESTA's debt has increased relative... subscribe to Premium to read more.
Shrinking Debt Financials
ESTA's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$16.6M
Investing
-$3.6M
Financing
$23.5M
ESTA's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
ESTA vs Medical Device Stocks
Establishment Labs Holdings Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.